지엘팜텍
Financials
Valuation Metrics
지엘팜텍's Market Cap is ₩699B. At end of 2025 it was ₩846B. Ranked #1545 of 2,421 in KR market (top 64%), #908 of 1,640 on KOSDAQ (top 55%), #170 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 69.95B KRW | KR#1,545/2,421 Sec#170/231 |
| Revenue | 38.21B KRW | KR#1,937/2,421 Sec#135/231 |
| Net Income | -107.1M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 49.00B KRW | KR#2,214/2,421 Sec#201/231 |
| Net Assets | 19.89B KRW | KR#2,288/2,421 Sec#213/231 |
| Employees | 25 | KR#2,225/2,421 Sec#208/231 |
| Value | ||
| P/B | 3.52x | KR#2,152/2,421 Sec#173/231 |
| P/S | 1.83x | KR#1,757/2,421 Sec#102/231 |
| EV/EBITDA | 408.86x | KR#1,551/2,421 Sec#108/231 |
| FCF Yield | -6.19% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -0.54% | KR#1,587/2,421 Sec#109/231 |
| ROA | -0.22% | KR#1,576/2,421 Sec#109/231 |
| Op. Margin | 0.59% | KR#1,552/2,421 Sec#110/231 |
| Revenue Growth | 29.75% | KR#396/2,421 Sec#39/231 |
| Earnings Growth | -288.02% | KR#1,268/2,421 Sec#89/231 |
| Financial Health | ||
| Debt Ratio | 146.38% | KR#1,883/2,421 Sec#208/231 |
| Total Debt | 24.97B KRW | KR#1,309/2,421 Sec#105/231 |
| FCF | -4.33B KRW | KR#1,468/2,421 Sec#115/231 |
| Cash | 3.25B KRW | KR#2,143/2,421 Sec#201/231 |
| Current Ratio | 0.98x | KR#1,746/2,421 Sec#174/231 |
| Net Debt/EBITDA | 96.88x | KR#1,519/2,421 Sec#106/231 |
| Performance | ||
| 1Y Return | -15.94% | KR#1,143/2,421 Sec#77/231 |
| 1M Return | 15.05% | KR#337/2,421 Sec#18/231 |
| From 52W High | -32.18% | KR#611/2,421 Sec#36/231 |
| 1Y MDD | -38.78% | KR#540/2,421 Sec#38/231 |
| Trading | ||
| Volume | 17,157 shares | KR#1,657/2,421 Sec#163/231 |
| Trading Value | 76.9M KRW | KR#1,671/2,421 Sec#169/231 |
| Foreign Own. | 0.74% | KR#2,134/2,421 Sec#208/231 |
| Per Share | ||
| EPS | -7 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,282 KRW | KR#2,244/2,421 Sec#201/231 |
Company Info
GL Pharm Tech, established in 2014 and headquartered in Seongnam-si, Gyeonggi-do, is a specialized enterprise in pharmaceutical research and development services and sales & marketing, listed on KOSDAQ in 2014. The company focuses on developing incrementally modified drugs using Drug Delivery System (DDS) technologies like controlled release and drug absorption enhancement. Its consolidated subsidiary, GL Pharma Co., Ltd., possesses hormone drug production facilities, which only a few domestic pharmaceutical companies have, and produces and sells pharmaceuticals, expanding its business into contract manufacturing and sales.